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Abstract. Anti-malarial drugs have been used in various ways to prevent malaria in the resident populations of
endemic areas for nearly 100 years. The primary aim of most early studies was to interrupt transmission. This was rarely
achieved, but administration of anti-malarial drugs either through medication of salt or by mass administration fre-
quently led to a marked reduction in the prevalence of malaria infection and in the incidence of clinical attacks.
Chemoprophylaxis is highly effective in reducing mortality and morbidity from malaria in young children and pregnant
women living in endemic areas, but is difficult to sustain and, in some studies, has impaired the development of naturally
acquired immunity. Intermittent preventive treatment, in which full therapeutic doses of a drug are given at defined
intervals, has the potential to provide some of the benefits of sustained chemoprophylaxis in pregnant women and young
children without some of its drawbacks and is a promising new approach to malaria control.
INTRODUCTION
The value of anti-malarial drugs in protecting short-term,
non-immune visitors to malaria-endemic areas from the seri-
ous consequences of malaria infection is generally recognized
but perhaps under-valued. Chemoprophylaxis has allowed a
tourist industry to develop in some areas that were previously
death traps for the non-immune, and prophylaxis has facili-
tated business travel and the economic development of many
malaria-endemic areas. However, the use of anti-malarial
drugs to protect the resident population of malaria-endemic
areas has always proved to be much more controversial. In
this paper, I review the various ways in which anti-malarial
drugs have been used for this purpose in the past (Table 1)
and discuss the current reawakening of interest in this ap-
proach to malaria control.
ANTI-MALARIALS AND REDUCTION OF
MALARIA TRANSMISSION
The primary objective of most early studies of widespread
distribution of anti-malarial drugs to the population of ma-
laria endemic areas was interruption of malaria transmission.
Two approaches have been tried: treatment of symptomatic
cases and mass drug administration.
Treatment of symptomatic cases. The idea that treatment
of symptomatic cases with an effective anti-malarial would
reduce transmission and thus provide indirect protection to
the population as a whole dates back to Robert Koch and the
early years of the 20th century.1 Quinine was used extensively
in Italy and elsewhere during the first part of the 20th century,
partly with this aim in mind. However, quinine has little or no
effect on gametocytes, a fact that was recognized by Celli,
although he advocated extensive use of the drug.1 Thus, it is
unlikely that treatment of cases with quinine had much im-
pact on overall transmission of the infection. Treatment of
clinical cases with a drug, such as an artemisinin, which kills
gametocytes as well as asexual parasites, is more likely to be
effective. Recent experience in Southeast Asia and in South
Africa supports this view. On the Thai-Burmese border, re-
placement of mefloquine with mefloquine-artesunate as first-
line treatment of patients with symptomatic malaria was as-
sociated with a substantial reduction in the incidence of Plas-
modium falciparum infection,2 and widespread use of
artemisinins may have contributed to a marked decline in the
overall incidence of malaria in Vietnam.3 In South Africa,
replacement of ineffective sulfadoxine-pyrimethamine (SP)
with an artemisinin-based combination therapy (ACT) was
again associated with a rapid decrease in the overall incidence
of falciparum malaria.4 However, in Vietnam and in South
Africa the introduction of artemisinins was associated with
the introduction of other malaria control measures: insecti-
cide treated nets (ITNs) in Vietnam and household residual
spraying in South Africa. Thus, although these observations
strongly suggest that introduction of ACTs for treatment of
clinical cases had an effect on the overall level of malaria
transmission in these low transmission areas, this has not been
proven definitively.
Mass drug administration. In the highly endemic areas of
Africa, in contrast to the situation in Southeast Asia and
South Africa, most malaria infections are asymptomatic and
go untreated, even when quite high levels of parasitemia are
present.5 In such situations, a significant reduction in the
transmission of malaria by administration of a gametocidal
drug is likely to be achieved only if asymptomatic as well as
symptomatic subjects are treated. Detecting the latter re-
quires a major investment in surveillance so the concept of
mass drug administration (MDA) was developed. During an
MDA, the whole population of a community known to con-
tain a number of asymptomatic subjects is treated without
determining who is infected.
Anti-malarials were distributed widely in endemic areas of
Italy during the 1920s and the 1930s, partly as personal pro-
phylaxis but also to reduce transmission (Figure 1). Increased
consumption of quinine was accompanied by a marked de-
crease in the incidence of malaria,1 but it is not certain that
this was cause and effect. Quinine was also used extensively
by Gorgas during the construction of the Panama Canal, in
part as personal prophylaxis for canal workers, but also to
reduce transmission (Figure 2).1 The use of MDAs to reduce
transmission became a more promising approach to malaria
control following the discovery of the 8-aminoquinolines,
which are gametocidal One of the first studies to investigate
the potential role of this class of drugs in interrupting trans-
mission in an endemic area was a trial carried out in a rubber
plantation in Liberia in 1930. Mass treatment of the popula-
tion of two camps with plasmoquine led to a marked decrease
in parasite prevalence and a reduction in the number of in-
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fected mosquitoes in the treated camps.6 During the 1960 s
and 1970s, a number of trials of MDA were undertaken in
Africa and Asia with the primary aim of interrupting trans-
mission. These trials have recently been reviewed elsewhere.7
The results of most of these early trials are difficult to assess
because they were not conducted in a way that would now be
considered obligatory for a community-randomized trial;
most involved before and after comparisons or comparisons
of single intervention and unmatched control areas and some
combined MDA with vector control. In nearly all cases, trans-
mission was not interrupted although there was a marked
reduction in parasite prevalence.
The most ambitious attempt to interrupt malaria transmis-
sion in a high transmission area of Africa using the MDA
approach was undertaken in Garki in northern Nigeria in the
1970s.8 Household spraying with a residual insecticide was
combined with several rounds of MDA with sulfalene-
pyrimethamine. Parasite and spleen rates decreased substan-
tially in the intervention communities, but transmission was
not interrupted and the intervention was generally considered
to have failed. However, episodes of clinical malaria, and
probably deaths, were reduced during the period of the in-
tervention.
The largest MDA program reported was conducted in
Nicaragua in 1981. A single round of treatment with chloro-
quine plus primaquine was given to approximately eight mil-
lion people.9 There was a marked decrease in the incidence of
malaria immediately after drug administration, but transmis-
sion was not interrupted and the incidence of malaria soon
returned to its previous level.
A recent study of MDA was undertaken in The Gambia
with the aim of delaying the onset of transmission in an area
where malaria is highly seasonal and transmission limited to a
few months of the year.10 Sulfadoxine-pyrimethamine and
artesunate were given to the whole of the population of 33
villages at the end of the dry season when gametocyte levels
are at their lowest. A reduction in the incidence of malaria
compared with that seen in nine control villages where pla-
cebo was distributed was observed during the month after the
administration of the drug combination, but no overall effect
on the incidence of malaria throughout the course of the ma-
laria transmission season was seen.
One success for MDA in achieving the goal of interruption
of transmission has been reported recently from the island of
Aneityum, Vanuatu. Eight rounds of MDA with chloroquine-
SP-primaquine combined with the introduction of ITNs and
environmental control measures led to the elimination of fal-
ciparum infection from the island.11
In most MDAs, medication has been given in the form of
tablets, sometimes under supervision. This ensures that an
effective dose is given, but if large populations are to be cov-
ered on a repeated basis, this approach to drug delivery is
demanding. In an attempt to overcome this problem, Pinotti
devised the concept of drug delivery through the use of medi-
cated salt.12 During the 1950s and 1960s, a number of trials of
medicated salt were undertaken in malaria-endemic areas.13
These generally achieved their objective of reducing the in-
cidence of clinical episodes of malaria, but only at the cost of
the rapid emergence of resistance.14,15 Studies in experimen-
tal systems have shown that exposure of malaria parasites to
a sub-therapeutic dose of an anti-malarial over a prolonged
period of time is the optimum way of inducing resistance. Use
of medicated salt is likely to have a similar effect and has no
place in malaria control.
Difficulties in delivery, problems with resistance, and the
lack of a safe and highly effective anti-gametocidal drug limit
the potential of MDAs in malaria control. MDAs may have a
role in the final phase of a combined elimination strategy, as
shown in Vanuatu.11 An MDA could also be useful in con-
trolling an epidemic in a situation in which it is anticipated
that transmission will decrease spontaneously within a short
time, for example, after a period of flooding or a civil distur-
bance that leads to a short-term refugee situation. If an MDA
TABLE 1
Approaches to the administration of anti-malarial drugs as a means of preventing malaria in the population of malaria-endemic communities
Approach Comments
Treatment of clinical cases Requires that a high proportion of infections are symptomatic and that patients have easy access to
treatment
Likely to be more effective if treatment includes a gametocidal drug
Medication of salt Produces sub-therapeutic but cumulative blood levels
Highly likely to induce resistance
Mass drug administration Involves administration of drug, usually in therapeutic doses, to infected and non-infected subjects
Usually has only a transitory effect on levels of parasitemia and clinical malaria
Chemoprophylaxis Involves the repeated administration of drug, usually at sub-therapeutic doses, over a sustained
period so as to obtain persistent protective blood levels
Intermittent preventive treatment Involves the administration of a therapeutic dose of drug over an intermittent and defined period
FIGURE 1. Distribution of antimalarials in Italy in the 1930s. (Ar-
chivio Casini, Sezione di storia della medicina, University of Rome
‘La Sapienza’).
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is contemplated in such a situation, it should be given as soon
as possible and the treatment regimen should incorporate a
gametocidal drug, preferably an artemisinin combined with a
longer acting partner.
ANTI-MALARIALS AND THE PREVENTION OF
MORTALITY AND MORBIDITY FROM MALARIA
Introduction. Protection of the indigenous populations of
malaria-endemic countries from malaria by regular adminis-
tration of anti-malarial drugs has never found favor with the
international malaria control community, although the opera-
tors of many mines and plantations have found it cost-
effective to protect their work force and their families from
malaria in this way. Nevertheless, when chemoprophylaxis
has been evaluated in this kind of situation, it has almost
always been found to be highly effective in reducing morbid-
ity and mortality from malaria, especially when targeted at
high risk groups such as young children and pregnant women.
Chemoprophylaxis in children. In 1956, McGregor and
others reported the results of a trial in The Gambia in which
children were given chloroquine weekly from birth until the
age of two years.16 Children who received chemoprophylaxis
had fewer episodes of malaria, grew better, and had a higher
mean hemoglobin and a lower gamma globulin concentration
than children in the control group. These findings were re-
produced in studies conducted subsequently in several other
countries in Africa.17
A large trial of chemoprophylaxis in children less than five
years of age was conducted in The Gambia in the early
1980s.18 More than 700 children were given chemoprophy-
laxis with Maloprim® (GlaxoSmithKline, Brentford, United
kingdom) (pyrimethamine plus dapsone) by village health
workers throughout the rainy season over a period of five
years. Overall mortality in children who received prophylaxis
was reduced by approximately 35%. Protected children had
fewer clinical attacks of malaria and a higher mean packed
cell volume than control children. These results were sus-
tained during several years of observation19 and are at least as
impressive as those obtained with ITNs. A study conducted
more recently in Tanzanian infants using the same anti-
malarial also showed a marked reduction in clinical attacks of
malaria and in the incidence of severe anemia.20
Chemoprophylaxis in pregnant women. The first reported
trial of chemoprophylaxis in pregnant women was undertaken
in a mission hospital in western Nigeria in 1964.21 This
showed that chemoprophylaxis with pyrimethamine led to a
substantial increase in birth weight in primigravidae and in
grand-multiparous women. Subsequent studies, conducted in
several countries in Africa, have confirmed the effect of
chemoprophylaxis on birth weight22 and shown that it also
results in an increase in maternal hemoglobin levels.23 Most
studies have shown that the protective effect of chemopro-
phylaxis is most marked in first and second pregnancies.
Drugs that have been used for chemoprophylaxis in preg-
nancy include chloroquine, pyrimethamine, proguanil, Mal-
oprim®, and mefloquine. On the basis of the result of trials of
chemoprophylaxis conducted in several countries in Africa,
the recommendation of the World Health Organization was,
until recently, that all pregnant women resident in areas of
moderate or high malaria transmission should receive chemo-
prophylaxis with chloroquine throughout the second and
third trimesters of pregnancy. However, this intervention has
rarely been implemented on any significant scale.
Objections to the use of targeted chemoprophylaxis. Why,
in the face of the impressive results discussed earlier, has
FIGURE 2. Building the Panama Canal. (Wellcome Library, London).
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chemoprophylaxis never been recommended for children
resident in malaria-endemic countries or, in the case of preg-
nant women, recommended but rarely implemented? Some
of the reasons why this is the case are now considered.
Sustainability. Sustaining compliance with prophylaxis is a
difficult but not an insurmountable challenge. In The Gam-
bia, one-third of villages sustained high levels of coverage
with chemoprophylaxis in young children over a period of five
years and another third achieved moderate levels of cover-
age.19 In this community, chemoprophylaxis was given by vil-
lage health workers who received no financial support from
the public health services and limited help from their com-
munities. It is likely that higher levels of coverage could have
been achieved if they had been paid. In most malaria-endemic
countries, a high proportion of pregnant women attend an
antenatal clinic at least once during pregnancy, but few attend
often enough to allow the distribution of weekly chemopro-
phylaxis. Thus, if this approach to malaria control is to be
followed, an alternative delivery system may be required. In
The Gambia, this was provided effectively by traditional birth
attendants.23
Safety. Drugs given on a regular basis to large numbers of
healthy children or pregnant women must be extremely safe.
No serious adverse events attributable to drug administration
have been reported during trials of chemoprophylaxis in chil-
dren, but the possibility that occasional serious adverse ef-
fects may have been missed cannot be excluded. In Sierra
Leone, but not in The Gambia, chemoprophylaxis with Mal-
oprim® resulted in hyperpigmented skin lesions, which disap-
peared after drug administration was stopped.24 There are
few data on the safety of anti-malarials when used for chemo-
prophylaxis in pregnancy because most studies have involved
only relatively small numbers of women and did not have the
power to detect uncommon effects or a small increase in an
adverse outcome of pregnancy. However, itching is one of the
main reasons why chemoprophylaxis with chloroquine is un-
popular among pregnant women.
Cost. Cost-effectiveness studies have shown that childhood
chemoprophylaxis with a drug that costs approximately $0.1
per administration and chemoprophylaxis in pregnancy are
both highly cost effective.25 However, donor funds might be
needed to introduce chemoprophylaxis on a national scale.
Impairment of the development of natural immunity. A ma-
jor concern over the use of chemoprophylaxis in young chil-
dren has been a fear that this will impair the development of
natural immunity. Few studies have investigated this possibil-
ity directly. In The Gambia, children who received chemo-
prophylaxis for 1−5 years experienced an increase in clinical
attacks of malaria during the year after chemoprophylaxis
was stopped, but the effect was statistically significant only in
those who had received anti-malarials from the ages of three
months to five years.26 During the first year after chemopro-
phylaxis was stopped, there were 10 deaths in children who
had received Maloprim® compared with four in a similar
number of control children (P  0.12), but survival curves
showed that the protection from death obtained from chemo-
prophylaxis taken during early years of life was sustained up
to 10 years of age.26 Because mortality rates decrease sub-
stantially after the age of five years, a very large trial involving
tens of thousands of children would be needed to completely
rule out a rebound mortality effect. A rebound effect was also
observed during a more recent study in Tanzania.20 In this
trial, the incidence of clinical malaria was significantly higher
during the second and third years of life in children who had
received chemoprophylaxis with Maloprim® during their first
year of life than in a group of control children.
Primigravidae are believed to acquire some immunity to
malaria through the acquisition of antibodies that interfere
with the binding of P. falciparum to chondroitin sulfate in the
placenta. Studies in Tanzania and in Kenya suggest that
chemoprophylaxis can interfere with the development of
these antibodies,27 and so if chemoprophylaxis is restricted to
first or second pregnancies this could increase the risk of
malaria in subsequent pregnancies. So far only one study has
investigated this possibility.28 No reduction in birthweight or
hemoglobin level was observed in secundigravidae who had
received chemoprophylaxis during their first pregnancy com-
pared with controls, but this study was small and a larger trial
is needed to substantiate this finding.
Induction of drug resistance. It would be anticipated that
widespread deployment of chemoprophylaxis in children and/
or pregnant women would increase the rate of spread of drug
resistant parasites, the extent of the effect being related to the
relative proportion of drug used for prophylaxis compared
with the overall use of the drug in the community. The in-
crease in drug use resulting from prophylaxis might be offset
to some extent by a reduction in the number of clinical epi-
sodes of malaria requiring treatment. The use of medicated
salt and the unrestricted use of chloroquine and pyrimeth-
amine, including their use for prophylaxis, in the 1960s is
likely to have contributed to the initial emergence and spread
of resistance to these drugs.13 However, there is little infor-
mation on whether the use of targeted chemoprophylaxis in
children or pregnant women has had this effect. In a study
from Tanzania,29 which is cited widely as evidence that this
has occurred, prophylaxis with Maloprim® was followed
within a few months by an increase in the prevalence of re-
sistant parasites in children who were receiving prophylaxis,
but also in control children resident in the same village who
were not taking the drug. It seems unlikely that chemopro-
phylaxis in approximately 10% of the population for just a
few months was responsible for replacement of most parasites
within the village by resistant strains. It is more likely that this
change was due to some other independent event. In The
Gambia, no increase in pyrimethamine resistance was noted
after five years of chemoprophylaxis with Maloprim® (Green-
wood B, unpublished data). Chemoprophylaxis will inevitable
lead to an increase in drug pressure, but this may be an ac-
ceptable price to pay if the benefits are substantial and it may
be possible to reduce this risk by the use of combination
therapy.
Role of chemoprophylaxis in current malaria control pro-
grams. The effectiveness of chemoprophylaxis in reducing
mortality and morbidity from malaria in young children and
in pregnant women has been demonstrated convincingly on
many occasions, and the difficulties of implementing chemo-
prophylaxis and its potential risks have probably been exag-
gerated. Constraints on the deployment of chemoprophylaxis
could be overcome in most cases using the increased financial
resources that are now available for malaria control. How-
ever, increasing drug pressure, impairment of the develop-
ment of natural immunity and difficulty in identifying a drug
that is safe and effective remain problems for this approach to
malaria control. Intermittent preventive treatment, which
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provides some of the benefits of chemoprophylaxis while re-
ducing some of its risks, may be a more promising way for-
ward.
INTERMITTENT PREVENTIVE TREATMENT
Introduction. Intermittent preventive treatment (IPT) de-
scribes the administration of a full therapeutic course of an
anti-malarial to at risk subjects at specified times regardless of
whether they are infected. IPT differs from chemoprophy-
laxis, which aims to sustain blood levels above the mean in-
hibitory concentration for a prolonged period, in producing
protective drug concentrations for only short periods of time
separated by periods when drug concentrations are below the
level necessary to inhibit parasite growth. Because SP is the
drug that has been used most widely for IPT in both pregnant
women and children, it is not known whether IPT achieves its
effect primarily by elimination of parasites or through the
long-acting, prophylactic effect of SP.
IPT in pregnant women (IPTp). Because of the difficulty
in sustaining chemoprophylaxis in pregnant women, Schultz
and others working in Malawi compared the effects of treat-
ment with a full course of SP given twice during pregnancy
with the effects of weekly chemoprophylaxis with chloro-
quine.30 The prevalence of low birth weight in the infants of
women who received IPT with SP was significantly lower than
that in women who received chemoprophylaxis with chloro-
quine. The protective effect against low birth weight of IPT
with SP has subsequently been confirmed in larger effective-
ness studies in Malawi, even when only one dose was given.31
In Kenya, a controlled trial showed that IPT with SP given
two or three times during pregnancy reduced the prevalence
of severe anemia in primigravidae and secundigravidae.32
However, a study in another area of Kenya showed that
women infected with human immunodeficiency virus (HIV)
required more than two or three doses of IPT to prevent
infection of the placenta.33 On the basis of these rather lim-
ited results, the World Health Organization now recommends
that IPT with SP, given at each antenatal clinic attendance
after quickening, should replace chemoprophylaxis as the
preferred chemotherapeutic method for the prevention of
malaria in pregnancy. However, there are still a number of
uncertainties over the use of IPTp. There are no data on the
effectiveness of IPTp in areas of low endemicity or in areas
where malaria transmission is highly seasonal. Because the
mode of action of SP when used for IPTp is uncertain, it is not
known whether in the increasing number of areas of Africa
where SP is losing its efficacy, SP should be replaced with a
long-acting drug such as mefloquine or whether a short acting
drug such as Lapdap® (GlaxoSmithKline) (proguanil plus
dapsone) would be as effective. The optimum approach to
IPTp in women who are HIV-positive is not known. Thus,
more research is needed if the full potential of this approach
to the control of malaria in pregnancy is to be obtained.
IPT in infants (IPTi). The IPT concept has recently been
applied to the prevention of malaria in infants. A study un-
dertaken in Tanzania by Schellenberg and others34 showed
that administration of a full dose of SP to infants at the time
that they received their second and third doses of DPT and
measles vaccines resulted in a 59% reduction in the inci-
dence of clinical attacks of malaria and a 50% reduction in the
incidence of severe anemia during the first year of life. A
second study undertaken in Tanzania in which amodiaquine
was given in a full therapeutic dose three times during the first
year of life at the time of regular infant check-up clinics
achieved similar impressive results.35 Importantly, there was
no rebound in malaria attacks or in anemia during the second
year of life in children who had received IPTi as infants. Trials
of IPTi with SP are nearing completion in Ghana and Kenya,
and further trials have started recently in Mozambique, Ga-
bon, and Kenya. The results of these trials will help to define
the epidemiologic conditions under which IPTi is effective.
However, there are still many unanswered questions about
the role of IPTi in malaria control. To address some of these
important questions (Table 2), an IPTi consortium compris-
ing several groups of investigators interested in this area of
research, the World Health Organization, and the United Na-
tions Children’s Fund has recently been formed and has re-
ceived support from the Bill and Melinda Gates Foundation.
IPT in children (IPTc). In high transmission areas, where
a major proportion of deaths and severe morbidity from ma-
laria occur during the first year of life, IPTi could make a
major contribution to reducing the burden of malaria as a
whole. However, in many areas of Africa, perhaps covering as
much as 50% of the population at risk, the major burden of
malaria is not in infants but in older children. This is espe-
cially the case in countries of the Sahel and sub-Sahel where
malaria transmission is intense but very seasonal. In such ar-
eas, IPTi, even if highly effective, would have only a limited
impact on the overall burden of malaria in children. Thus, a
pilot study in Senegal is exploring whether the IPT principle
can be applied to older children (Cisse B and others, unpub-
lished data). In this study, SP and one dose of artesunate have
been given to all eligible children less than five years old in a
community with a total population of approximately 12,000
three times at one monthly intervals throughout the peak
period of malaria transmission. This intervention resulted in a
reduction in the incidence of clinical attacks of malaria of
approximately 85%. Observations are now under way to de-
termine if this impressive effect is followed by a rebound. For
the purpose of this trial, the anti-malarial drug was adminis-
tered by project staff. Devising an effective method of deliv-
ery, which may be site specific, will be an important pre-
TABLE 2
Outstanding issues on the use of IPTi*
• Lack of knowledge of the efficacy of IPTi in different
epidemiologic situations
• Lack of knowledge of the mode of action of SP when used for
IPTi
• The possible impact of co-administration of an anti-malarial
drug at the time of vaccination on the immune response to that
vaccine
• Whether administration of an anti-malarial drug at the time of
vaccination would enhance or detract from compliance with
routine immunization
• The identity of drugs that could be used to replace SP for IPTi
in areas of high SP resistance
• The safety of SP and alternative drugs when used on a large
scale for IPTi
• The effect of IPTi on the development of natural immunity
• The cost efficacy of IPTi in different epidemiologic situations
• Whether IPTi could be readily implemented on a programmatic
scale
* IPTi  intermittent preventive treatment in infants; SP  sulfadoxine-pyrimethamine.
ANTIMALARIAL DRUGS AND THE PREVENTION OF MALARIA 5
requisite for this approach to malaria control which is likely to
be most effective in areas of intense, seasonal transmission
where drug administration may be required on only two to
four occasions each year.
CONCLUSION
The use of drugs to prevent malaria in the population of
malaria-endemic areas has a long history. It has progressed
from mass drug administration involving the whole popula-
tion through sustained chemoprophylaxis targeted at risk
groups to IPT in which drug administration is reduced to the
minimal level required to achieve a useful protective effect.
The use of anti-malarial drugs to prevent malaria will always
involve balancing the level of protection achieved with the
cost of the drug, its side effects, and its impact on the devel-
opment of natural immunity and drug resistance. If the initial
results of studies in infants and children are confirmed, the
IPT approach may offer the optimum balance that can be
achieved.
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